Primary Biliary Cholangitis Market is Predicted to Exhibit Remarkable Growth by 2032, Estimates DelveInsight | Key Companies – Genfit, Zydus Cadila, Genkyotex, and CymaBay Therapeutics
The Primary Biliary Cholangitis market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.
Primary Biliary Cholangitis: An Overview
Primary biliary cirrhosis (PBC), now known as primary biliary cholangitis, is an autoimmune disorder that leads to the gradual destruction of intrahepatic bile ducts resulting in periportal inflammation, cholestasis. Prolonged hepatic cholestasis subsequently leads to cirrhosis and portal hypertension.
Primary biliary cirrhosis is the most common cholestatic disease of middle-aged women in the United States. Researchers theorize that patient with PBC has both genetic predisposition with the right environmental trigger. The prevalence of the disease is 100-fold higher in first-degree relatives of the index patient, which strongly suggests a genetic predisposition.
Primary Biliary Cholangitis Market Key Facts
-
The total primary biliary cholangitis (PBC) diagnosed prevalent population in the 7MM countries was estimated to be 253,100+ cases in 2020.
-
The US accounts for the highest population of patients diagnosed with PBC among 7MM countries; the US accounted for 106,000+ cases in 2020.
-
Among the European countries, Germany had the highest population of PBC with 32,000+ cases, followed by the UK, which had 24,900+ cases in 2020. On the other hand, France had the lowest PBC population.
-
According to DelveInsight’s analysis, PBC is more prominent in females than in comparison to males.
Primary Biliary Cholangitis Market
The Primary Biliary Cholangitis market size is anticipated to increase during the study period owing to the growing awareness, improved management, increased prevalence, and the expected launch of novel therapies.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Primary Biliary Cholangitis market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives a thorough detail of the Primary Biliary Cholangitis market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Primary Biliary Cholangitis Market Drivers
-
Early diagnosis
-
Better risk stratification
-
Research and development of upcoming therapies
-
Discovery and targeting of novel pathways
Primary Biliary Cholangitis Epidemiology
The epidemiology section covers insights into the historical and current Primary Biliary Cholangitis patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Primary Biliary Cholangitis Epidemiology Segmentation
-
Total Diagnosed Prevalent cases of Primary biliary cholangitis
-
Gender-specific cases of Primary biliary cholangitis
-
Gender-specific cases of Primary biliary cholangitis
Primary Biliary Cholangitis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Primary Biliary Cholangitis market or expected to get launched in the market during the study period. The analysis covers Primary Biliary Cholangitis market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Primary Biliary Cholangitis Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.
Get the PDF Sample of the Report:- https://www.delveinsight.com/sample-request/primary-biliary-cholongitis-market
Primary Biliary Cholangitis Therapeutics Analysis
Some of the key companies in the Primary Biliary Cholangitis Market include:
-
Genfit
-
Zydus Cadila
-
Genkyotex SA
-
CymaBay Therapeutics
And Others.
Primary Biliary Cholangitis Therapies covered in the report include:
-
Seladelpar
-
Elafibranor
-
Setanaxib
-
Saroglitazar Mg
And many others.
Get More Detailed Insights into the Emerging Therapies & Key Companies:- https://www.delveinsight.com/sample-request/primary-biliary-cholongitis-market
Table of Content
1. Key Insights
2. Executive Summary
3. Primary Biliary Cholangitis Competitive Intelligence Analysis
4. Primary Biliary Cholangitis Market Overview at a Glance
5. Primary Biliary Cholangitis Disease Background and Overview
6. Primary Biliary Cholangitis Patient Journey
7. Primary Biliary Cholangitis Epidemiology and Patient Population
8. Primary Biliary Cholangitis Treatment Algorithm, Current Treatment, and Medical Practices
9. Primary Biliary Cholangitis Unmet Needs
10. Key Endpoints of Primary Biliary Cholangitis Treatment
11. Primary Biliary Cholangitis Marketed Products
12. Primary Biliary Cholangitis Emerging Therapies
13. Primary Biliary Cholangitis Seven Major Market Analysis
14. Attribute Analysis
15. Primary Biliary Cholangitis Market Outlook (7 major markets)
16. Primary Biliary Cholangitis Access and Reimbursement Overview
17. KOL Views on the Primary Biliary Cholangitis Market.
18. Primary Biliary Cholangitis Market Drivers
19. Primary Biliary Cholangitis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Request Sample Report here:- https://www.delveinsight.com/sample-request/primary-biliary-cholongitis-market
Other Latest Reports By DelveInsight
DelveInsight’s “Metrorrhagia Market” report delivers an in-depth understanding of the historical and forecasted epidemiology, the Metrorrhagia market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan) as well as the emerging therapies and key companies in the therapeutic domain.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
